Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -13.57% is 46% above its 5-year average of -25.19%, near the high end of its 5-year range (-79.04%–-10.92%).
As of the fiscal period ended Tuesday, June 30, 2026. 10.82% below its 12-month average of -12.25%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-06-30): -0.01%.
RETURN ON ASSETS (ROA)
-13.57%
RETURN ON ASSETS (ROA) AVG TTM
-12.25%
RETURN ON ASSETS (ROA) AVG 3Y
-12.55%
RETURN ON ASSETS (ROA) AVG 5Y
-25.19%
RETURN ON ASSETS (ROA) AVG 10Y
-55.46%
RETURN ON ASSETS (ROA) AVG 15Y
-53.76%
RETURN ON ASSETS (ROA) AVG 20Y
-71.84%
CURRENT VS TTM AVG
-10.82%
CURRENT VS 3Y AVG
-8.15%
CURRENT VS 5Y AVG
+46.14%
CURRENT VS 10Y AVG
+75.53%
CURRENT VS 15Y AVG
+74.76%
CURRENT VS 20Y AVG
+81.11%
SECTOR MEDIAN · HEALTHCARE
-25.07%
median of 450 covered companies
CURRENT VS SECTOR MEDIAN
+45.86%
vs the sector median at left
Aytu BioPharma, Inc.
Market Cap
$21.90M
Return on Assets (ROA)
-13.57%
TTM Avg
-12.25%
3Y Avg
-12.55%
5Y Avg
-25.19%
Market Cap
$20.93M
Return on Assets (ROA)
-393.39%
TTM Avg
-225.59%
3Y Avg
-343.91%
5Y Avg
-343.91%
Market Cap
$24.44M
Return on Assets (ROA)
-116.81%
TTM Avg
-53.20%
3Y Avg
-39.87%
5Y Avg
-35.95%
Market Cap
$18.82M
Return on Assets (ROA)
-39.68%
TTM Avg
-29.52%
3Y Avg
-26.86%
5Y Avg
-20.28%
Market Cap
$18.77M
Return on Assets (ROA)
-548.74%
TTM Avg
-346.44%
3Y Avg
-242.08%
5Y Avg
-167.09%
Market Cap
$25.48M
Return on Assets (ROA)
-40.73%
TTM Avg
-51.29%
3Y Avg
-88.21%
5Y Avg
-85.48%
Market Cap
$16.58M
Return on Assets (ROA)
-67.58%
TTM Avg
-90.98%
3Y Avg
-83.38%
5Y Avg
-70.12%
Market Cap
$16.54M
Return on Assets (ROA)
-116.60%
TTM Avg
-66.28%
3Y Avg
-71.56%
5Y Avg
-63.10%
Market Cap
$27.31M
Return on Assets (ROA)
-49.53%
TTM Avg
-17.16%
3Y Avg
-133.18%
5Y Avg
-213.67%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aytu BioPharma, Inc. (AYTU) | $21.90M | -13.57% | -12.25% | -12.55% | -25.19% |
| Actuate Therapeutics Inc (ACTU)vs › | $20.93M | -393.39% | -225.59% | -343.91% | -343.91% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | -116.81% | -53.20% | -39.87% | -35.95% |
| Cosmos Health Inc. (COSM)vs › | $18.82M | -39.68% | -29.52% | -26.86% | -20.28% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | -548.74% | -346.44% | -242.08% | -167.09% |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.48M | -40.73% | -51.29% | -88.21% | -85.48% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.58M | -67.58% | -90.98% | -83.38% | -70.12% |
| Dyadic International, Inc. (DYAI)vs › | $16.54M | -116.60% | -66.28% | -71.56% | -63.10% |
| GridAI Technologies Corp. (GRDX)vs › | $27.31M | -49.53% | -17.16% | -133.18% | -213.67% |
| BioCardia, Inc. (BCDA)vs › | $16.22M | -154.34% | -227.23% | -240.86% | -184.63% |
ROA
-13.6%
ROE
-40.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-06-30 | -13.57% |
| 2025-06-30 | -10.92% |
| 2024-06-30 | -13.33% |
| 2023-06-30 | -12.37% |
| 2022-06-30 | -79.04% |
| 2021-06-30 | -21.94% |
| 2020-06-30 | -8.89% |
| 2019-06-30 | -135.84% |
| 2018-06-30 | -48.38% |
| 2017-06-30 | -150.07% |
| 2016-06-30 | -115.76% |
| 2015-06-30 | -42.37% |
| 2014-08-31 | -46.43% |
| 2013-08-31 | -592.80% |
| 2012-08-31 | -471.85% |
| 2011-08-31 | -599.01% |
| 2010-08-31 | -222.47% |
| 2009-08-31 | -140.72% |
| 2008-08-31 | -77.18% |
| 2007-08-31 | -82.04% |
